# Thymmune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thymmune-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.thymmune.com
- Total disclosed funding: $7M
- Latest round: Seed (Mar 1, 2023)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2019 by CEO Stan Wang, Thymmune Therapeutics, Inc., a.k.a. Thymmune Therapeutics is a biotechnology company that is developing scalable therapies for aging and disease by utilizing its approach in iPSC-thymic cell manufacturing, which helps in generating off-the-shelf cells at scale. In March 2023, Thymmune Therapeutics raised USD 7 million in seed funding led by Pillar Companies, with participation from New York Blood Center. This funding was part of a larger USD 13 million seed round.

The company is developing a pipeline of therapies to treat immunodeficiencies, immunodeficiencies, transplant-related, and autoimmune disorders. Thymmune Therapeutics leverages its machine learning-enabled thymic engineering platform for the mass production of iPSC-derived thymic cells to restore immune function.

The company plans to use its proceeds from March 2023 funding to advance its lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies, as well as expand into additional indications across areas of unmet clinical need in immunology and develop its thymic cell engineering platform.

## Funding rounds

- Seed, Mar 1, 2023, $7M — New York Blood Center, Pillar

## Investors

- New York Blood Center — Seed
- Pillar (https://capitalatlas.ai/funds/pillar) — Seed